Welcome Guest | Register / Login

Insight Pharma Reports Market Research Reports

Sort By
Title Published Price Buy Now
Biomarkers in Alzheimer's Disease
By Insight Pharma Reports
Overview Biomarkers in Alzheimer's Disease is focused on biomarker identification and development in patients with Alzheimer's Disease. This report focuses on the Alzheimer's Disease space featured in the parent report, hi...
Aug 2014 $ 699
Biomarkers in Amyotrophic Lateral Sclerosis
By Insight Pharma Reports
Overview Biomarkers in Amyotrophic Lateral Sclerosis is focused on the biomarker identification and development in patients with Amyotrophic Lateral Sclerosis (ALS). This report focuses on the ALS space featured in the par...
Aug 2014 $ 699
Biomarkers in Parkinson's Disease
By Insight Pharma Reports
Overview Biomarkers in Parkinson's Disease is focused on the biomarker identification and development in patients with Parkinson's Disease. This report focuses on the Parkinson's Disease space featured in the parent r...
Aug 2014 $ 699
Therapies for Solid Tumors: Pipelines, Markets, and Business Considerations
By Insight Pharma Reports
As our understanding of cancer has progressed, newer therapies, such as various targeted therapies and immunotherapy, have become an important part of today's cancer treatment regimens. This report focuses on pharmacological therapies-in particula...
Oct 2012 $ 1495
Competitor Analysis: CMV Vaccines & Therapeutics
By Insight Pharma Reports
The present Competitive Intelligence Report about CMV Vaccines & Therapeutics provides a competitor evaluation in the field of prophylactic vaccines and therapeutic antibodies, antisense, proteins, cells and small molecules against infection w...
Aug 2012 $ 266
Alzheimer's Disease: Clinical Pipelines, R&D Challenges, and Future Directions - Overview
By Insight Pharma Reports
Alzheimer’s disease is an extraordinarily active realm of research, with nearly 100 products in clinical development and many more at the discovery and preclinical stages. The competition in this arena is fierce, but the company that produce...
Jun 2012 $ 595
Competitor Analysis: RSV Vaccines and Therapeutics
By Insight Pharma Reports
The present Competitive Intelligence Report about RSV Vaccines & Therapeutics provides a competitor evaluation in the field of prophylactic vaccines and therapeutic antibodies, small molecules and RNAi against infection with respiratory syncyt...
Jun 2012 $ 333
2010 Biosimilar Prescribing Outlook
By Insight Pharma Reports
This study - designed, executed and analyzed by research professionals from the drug development and commercialization industry - sheds light on prescribers' views of biosimilars. It is based on interviews with 264 physicians in the United Sta...
Jun 2012 $ 750
Competitor Analysis: Pseudomonas Aeruginosa Vaccines and Therapeutics
By Insight Pharma Reports
The present Competitive Intelligence Report about Pseudomonas aeruginosa Vaccines & Therapeutics provides a competitor evaluation in the field of prophylactic vaccines and therapeutic antibodies, peptides and small molecules as well as DNA-, R...
May 2012 $ 266
Competitor Analysis: Staphylococcus aureus Vaccines and Therapeutics
By Insight Pharma Reports
The present Competitive Intelligence Report about prophylaxis and therapy of S. aureus infections provides a competitor evaluation in the field of molecules for prevention or treatment of Staphylococcus aureus infections as of May 2012. Purchase o...
May 2012 $ 399
Competitor Analysis: Janus Kinase (JAK) Inhibitors
By Insight Pharma Reports
The present Competitive Intelligence Report  about new developments in the pipeline of inhibitors of the janus-associated kinase (JAK) provides a competitor evaluation in the field of active R&D projects from preclinical stages up to mark...
May 2012 $ 394
Gauging the Biosimilar Effect: Will the Market Boom or Bust?
By Insight Pharma Reports
It was supposed to be the "epoch of biosimilars", or drugs that copied existing biologics but had the potential to be more cost-effective. Yet five years later, biosimilars have failed to reach their forecasted potential of $16.4 billion...
Jan 2012 $ 895
Biosimilar Drugs in Europe: Threat or Opportunity to Innovation?
By Insight Pharma Reports
Between now and 2019, a vast range of blockbuster drugs will go off patent, opening the floodgates in the EU to the biosimilars market. Already established there since 2006, biosimilars are set to be worth between $2.25 billion and $4.8 billion by...
Nov 2011 $ 595
Pharmaceuticals Brand PR: Developing Engaging Campaigns and Measuring ROI
By Insight Pharma Reports
The value of PR can seem immeasurable in brand positioning. Yet, in an age of budgetary juggling by marketing departments, the drive to scrutinize ROI is increasingly important. What' s more, as expectations on PR outcomes increase - in part d...
Sep 2011 $ 495
Kinase-Targeted Therapeutics: Development Pipelines, Challenges, and Opportunities
By Insight Pharma Reports
The field of kinase modulation is one of the most active in the biopharmaceutical industry. About 20 kinase inhibitors are approved for marketing in the United States and at least another 250 are in clinical evaluation. Kinases make up a veritable...
Aug 2011 $ 595
Pharma Marketing Excellence: Lessons From Experiences
By Insight Pharma Reports
Marketing excellence. Over the past five years, those two words have been the subject of hype and the focus of management attention. As the pharmaceutical industry struggles with market maturation and weakening product pipelines, marketing excelle...
Aug 2011 $ 595
The Impact of iPad on Pharma: A Primer
By Insight Pharma Reports
With the launch of Apple's iPad in April 2010, the way we use technology changed forever. Instant, portable and quick, the iPad is expected to sell 50 million units in 2011 alone.Its impact on Pharma is still being measured, but fo...
Jul 2011 $ 295
Biosimilars Regulatory Update: an evolving landscape
By Insight Pharma Reports
They’re costly to develop, fraught with potential patient safety concerns and subject to regulations that have yet to be written.Yet for the pharmaceutical industry, biosimilar monoclonal antibodies (mAbs) represent a potential treasu...
Feb 2011 $ 395